These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
269 related items for PubMed ID: 11834427
21. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG. Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303 [Abstract] [Full Text] [Related]
22. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. Sartorio A, Ortolani S, Galbiati E, Conte G, Vangeli V, Arosio M, Porretti S, Faglia G. J Endocrinol Invest; 2001 Apr; 24(4):224-30. PubMed ID: 11383908 [Abstract] [Full Text] [Related]
23. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A. J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530 [Abstract] [Full Text] [Related]
24. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA. J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080 [Abstract] [Full Text] [Related]
25. Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults. Rodríguez-Arnao J, James I, Jabbar A, Trainer PJ, Perrett D, Besser GM, Ross RJ. Clin Endocrinol (Oxf); 1998 Apr; 48(4):455-62. PubMed ID: 9640412 [Abstract] [Full Text] [Related]
26. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD). Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A. Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776 [Abstract] [Full Text] [Related]
27. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. J Clin Endocrinol Metab; 1997 Feb; 82(2):550-5. PubMed ID: 9024252 [Abstract] [Full Text] [Related]
28. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Gómez JM, Gómez N, Fiter J, Soler J. Horm Metab Res; 2000 Feb; 32(2):66-70. PubMed ID: 10741688 [Abstract] [Full Text] [Related]
29. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. Janssen YJ, Hamdy NA, Frölich M, Roelfsema F. J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153 [Abstract] [Full Text] [Related]
30. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment. Spagnoli A, Branca F, Spadoni GL, Cianfarani S, Pasquino AM, Argirò G, Vitale S, Robins SP, Boscherini B. J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806 [Abstract] [Full Text] [Related]
31. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G. J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162 [Abstract] [Full Text] [Related]
32. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025 [Abstract] [Full Text] [Related]
33. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. Hansen TB, Brixen K, Vahl N, Jørgensen JO, Christiansen JS, Mosekilde L, Hagen C. J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096 [Abstract] [Full Text] [Related]
34. Growth hormone status during long-term hexarelin therapy. Rahim A, O'Neill PA, Shalet SM. J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671 [Abstract] [Full Text] [Related]
38. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. Gürlek A, Gedik O. J Endocrinol Invest; 2001 Jun; 24(6):408-14. PubMed ID: 11434664 [Abstract] [Full Text] [Related]
39. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Lanes R, Gunczler P, Esaa S, Weisinger JR. Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321 [Abstract] [Full Text] [Related]
40. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Kužma M, Kužmová Z, Zelinková Z, Killinger Z, Vaňuga P, Lazurová I, Tomková S, Payer J. Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]